Karyopharm Therapeutics (KPTI) Stock Price, Quote, News & History | Benzinga

Karyopharm Therapeutics Inc (KPTI) Stock Price, Quote, News & History

KPTINASDAQ

Trade with Public

Trade with Public

$1.82

-0.18-9%

At close: Aug 19, 5:00 PM EST

$1.82

-0.18-8.98%

Pre-Market: 4:27 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$1.82

Volume / Avg.

1.17K / 1.22M

Day Range

- - -

52 Wk Range

1.79 - 10.99

Market Cap

$41.29M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

22

Short Interest

33.48%

Days to Cover

2.67

Recent Karyopharm Therapeutics Inc. News

Crude Oil Gains 1%; Apple Shares Tumble After Q3 Results

Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, materials stocks down 2.7%. Apple beats estimates, shares down 9%.

Avi Kapoor

Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings

US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon shares jump 14% after posting strong Q2 results.

Avi Kapoor

This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, initiations. See other analysts' views on HTFL, SKYH, FTH.

Avi Kapoor

Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Karyopharm, Apple, Guardant Health, Pagaya Tech.

Avi Kapoor

This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-65.35M

Investing Cash Flow (TTM)

2.97M

Financing Cash Flow (TTM)

78.60M

Free Cash Flow (TTM)

-65.35M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

16.22M

Analyst Trends and Forecast

4

Mar

1

Apr

1

May

1

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$232.71M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

0.24

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-780.93%

Earnings Yield % (FWD)

-282.02%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$14.56

Company Debt

Total Debt

$249.94M

LT Debt

$209.63M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$54.98M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$1.82

Volume / Avg.

1.17K / 1.22M

Day Range

- - -

52 Wk Range

1.79 - 10.99

Market Cap

$41.29M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

22

Short Interest

33.48%

Days to Cover

2.67

About

Sector

Health Care

Industry

Biotechnology

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and oth...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Karyopharm Therapeutics (KPTI) stock?

A

You can purchase shares of Karyopharm Therapeutics (NASDAQ:KPTI) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Karyopharm Therapeutics (KPTI) competitors?

A

Other companies in Karyopharm Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Karyopharm Therapeutics (KPTI) stock?

A

Karyopharm Therapeutics has a consensus price target of $16.44.

Q

What is the current price for Karyopharm Therapeutics (KPTI)?

A

The stock price for Karyopharm Therapeutics (NASDAQ: KPTI) is $1.8204 last updated August 21, 2026 at 4:41 AM EDT.

Q

Does Karyopharm Therapeutics (KPTI) pay a dividend?

A

There are no upcoming dividends for Karyopharm Therapeutics.

Q

When is Karyopharm Therapeutics (NASDAQ:KPTI) reporting earnings?

A

Karyopharm Therapeutics does not have any upcoming earnings scheduled.

Q

Is Karyopharm Therapeutics (KPTI) going to split?

A

There is no upcoming split for Karyopharm Therapeutics.

Q

What sector and industry does Karyopharm Therapeutics (KPTI) operate in?

A

Karyopharm Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.